SCHEMBL25193063

SCHEMBL25193063

CN1CCN(C(=O)N(O)Cc2ccc(Nc3ccc(C(C)(C)C)cc3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ RORC P51449 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ TRPV1 Q8NER1 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25188470 0.84 RORC (0.42) ALOX15HPGDRORCRAB9ASMN1; SMN2
SCHEMBL25187883 0.81 HTT (0.44) HPGDRAB9ASMN1; SMN2NPC1CYP1A2
SCHEMBL25189127 0.81 RORC (0.42) ALOX15HPGDRORCRAB9ATRPV1
SCHEMBL25190447 0.81 RORC (0.41) ALOX15HPGDRORCRAB9ASMN1; SMN2
SCHEMBL25190279 0.81 RORC (0.42) ALOX15HPGDRORCRAB9ASMN1; SMN2
SCHEMBL25183896 0.79 NR1H4 (0.46) SMN1; SMN2TRPV1MAPTEPHX2
SCHEMBL25200167 0.77 MAPT (0.44) RORCTRPV1ALDH1A1KDM4EMAPT
SCHEMBL25194563 0.77 RIPK1 (0.44) RORCSMN1; SMN2MAPTEPHX2
SCHEMBL25187989 0.75 HDAC3 (0.44) RORCRAB9ATRPV1EPHX2
SCHEMBL25183890 0.75 RIPK1 (0.46) RAB9ASMN1; SMN2NPC1TRPV1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 — — CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 — — US disclosed
CN-115151252-A Iron death inhibitors diarylamine para-acetamides 维泰瑞隆有限公司 2022-10-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 ALOX15 164/4885HPGD 522/4885RORC 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback